test

Ryan Cappelli

@Prosight Management, Lp

Latest period2024 - Q3ReportedManaged Assets$406.357MTotal holdings45
Assets growth rate21.46%Assets growth rate (2-Q avg)7.27%Continuous growth in asset value1 quarters

Portfolio positions

This chart displays the top 10 holdings in Prosight Management, Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 45 positions.

Assets under management

The assets under management (AUM) of Prosight Management, Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 406.357M in assets, with a quarterly growth rate of 21.46% and a 2-quarter average growth rate of 7.27%. The portfolio is managed by Ryan Cappelli, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
GLPGGalapagos Nv
Recent Activity
Decreased -23.78%
7.29%
$29.62M
1.029M shares@ $28.8 avg price
ROIVRoivant Sciences Ltd
Recent Activity
Decreased -13.92%
4.89%
$19.866M
1.722M shares@ $11.54 avg price
ZBHZimmer Biomet Holdings Inc
Recent Activity
Decreased -2.58%
4.4%
$17.877M
165,602 shares@ $107.96 avg price
ZYMEZymeworks Inc
Recent Activity
Decreased -22.23%
2.84%
$11.516M
917,599 shares@ $12.55 avg price
CYTKCytokinetics Inc
Recent Activity
Decreased -16.21%
2.51%
$10.175M
192,700 shares@ $52.8 avg price
ERASErasca Inc
Recent Activity
Decreased -27.85%
1.34%
$5.416M
1.984M shares@ $2.73 avg price
COGTCogent Biosciences Inc
Recent Activity
Decreased -17.83%
1.1%
$4.437M
410,830 shares@ $10.8 avg price
VKTXViking Therapeutics Inc
Recent Activity
Decreased -58.26%
0.75%
$3.039M
48,000 shares@ $63.31 avg price
VINCVincerx Pharma Inc
Recent Activity
Decreased -11.32%
0.39%
$1.58M
2.207M shares@ $0.72 avg price
OVIDOvid Therapeutics Inc
Recent Activity
Decreased -32.16%
0.22%
$860,465
729,208 shares@ $1.18 avg price